MEREO BIOPHARMA GROUP PLC (MREO)

Every figure this model derived for MREO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 30,118,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 33,401,000 AssetsCurrent 2026-06-30
current liabilities 5,677,000 LiabilitiesCurrent 2026-06-30
equity 28,652,000 StockholdersEquity 2026-06-30
interest expense 87,000 InterestExpense 2026-06-30
ocf -25,346,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 500,000 Revenues 2025-12-31
sbc 6,177,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up MREO on one particular measure came for.

RatioValue
current ratio5.88
current ratio reported5.88
dilution pct7.78
interest cover-393.11
sbc pct revenue1235.4

What to be careful about

What this model itself distrusts about MREO's figures. Written by the derivation as it ran, not added afterwards.